CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs

CapsoVision, Inc

2026-Q1 EPS reported -$0.15 revenue$2,792,000

Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.
Gross margin 48% vs 54% YoY due to impact of U.S. trade policies and tariffs.
Operating expenses $8.4M, up $1.5M from CMOS sensor development with Canon and Colon clinical trials.
Cash $17.9M; completed $14M PIPE financing on March 16, 2026.
Pipeline: AI-assisted reading feature on track for mid-2026 FDA clearance; CapsoCam Colon 510(k) submission Q3 2026; pancreatic cancer study enrolled first patient May 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.